Wenjing Fan, Tingting Tang, Qian Zeng, Hengquan Wan, Simin Zhao, Agyare Oware Kwabena, Zhisheng Jiang, Shunlin Qu
Pathophysiology Department, Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang City, Hunan Province 421001, PR China; Emergency Department, The Second Affiliated Hospital, University of South China, Hengyang City, Hunan Province 421001, PR China.
Pathophysiology Department, Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang City, Hunan Province 421001, PR China.
Clin Chim Acta. 2020 May;504:7-14. doi: 10.1016/j.cca.2020.01.007. Epub 2020 Jan 13.
Interleukin-1β (IL-1β) is a vital cytokine that plays an important role in regulating immune responses to infectious challenges and sterile insults. In addition, two endogenous inhibitors of functional receptor binding, IL-1 receptor antagonist (IL-1Ra), complete the family. To gain biological activity, IL-1β requires processing by the protease caspase-1 and activation of inflammasomes. Numerous clinical association studies and experimental approaches have implicated members of the IL-1 family, their receptors, or components of the processing machinery in the underlying processes of cardiovascular diseases. Here, we summarize the current state of knowledge regarding the pro-inflammatory and disease-modulating role of the IL-1 family in aneurysm. We discuss clinical evidence, signalling pathway, and mechanism of action and last, lend a perspective on currently developing therapeutic strategies involving IL-1β in aneurysm.
白细胞介素-1β(IL-1β)是一种重要的细胞因子,在调节对感染性挑战和无菌性损伤的免疫反应中发挥重要作用。此外,两种功能性受体结合的内源性抑制剂——白细胞介素-1受体拮抗剂(IL-1Ra),完善了这个家族。为了获得生物活性,IL-1β需要蛋白酶半胱天冬酶-1进行加工处理并激活炎性小体。众多临床关联研究和实验方法表明,IL-1家族成员、它们的受体或加工机制的组成部分参与了心血管疾病的潜在发病过程。在此,我们总结了目前关于IL-1家族在动脉瘤中促炎和疾病调节作用的知识现状。我们讨论了临床证据、信号通路和作用机制,最后,对目前正在开发的涉及IL-1β治疗动脉瘤的策略进行了展望。